Tag: Nasdaq:ALT

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the...

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:ALT

SATO Oyj – Managers’ Transactions

Ajay Rajan joins Protean eGov Technologies Ltd. as Managing Director & Chief Executive Officer

Quobly secures €115 million Series A to bring silicon-based quantum computers to market

Tag: Nasdaq:ALT

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the...

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us